The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combination immunotherapy for high-risk and advanced melanoma patients.
A. I. Riker
No relevant relationships to disclose
N. N. Vahanian
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
C. J. Link
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
L. Tennant
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
W. J. Ramsey
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
G. R. Rossi
Employment or Leadership Position - Newlink Genetics
Stock Ownership - Newlink Genetics
Other Remuneration - Newlink Genetics
L. C. Alsfeld
No relevant relationships to disclose
E. Davila
No relevant relationships to disclose
M. Harrison
No relevant relationships to disclose